What is the success rate of stem cell therapy for Heart Failure & Cardiac Repair?
A reliable success rate for heart-failure cell therapy is not established. Ejection fraction, exercise capacity, symptoms, hospitalisation and survival are different endpoints and should not be merged into one percentage. A provider should not promise medication reduction or functional improvement from an uncontrolled clinic cohort. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
What the evidence shows for Heart Failure & Cardiac Repair
Human heart-failure cell-therapy studies vary substantially by cell product, ischaemic or non-ischaemic cause, route, comparator and endpoint. Some studies report changes in imaging, exercise capacity or biomarkers, but consistent improvement in hospitalisation or survival has not been established for a marketed cell product. Exploratory subgroup findings should not be converted into a predictable response rate. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Heart Failure & Cardiac Repair: full overview → · Heart Failure & Cardiac Repair cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Heart Failure & Cardiac Repair: cell-therapy evidence and registered trials
- How much does stem cell therapy for Heart Failure & Cardiac Repair cost? (2026)
- Heart Failure & Cardiac Repair stem cell therapy — your questions answered (2026)
- Heart Failure & Cardiac Repair: cell-therapy evidence by therapy class
- MSC vs HSCT for Heart Failure & Cardiac Repair: what the registries show